Description
C-terminal fragment of human growth hormone studied for lipolysis
AOD 9604 is a tailored peptide fragment derived from human growth hormone (HGH), engineered to specifically target fat metabolism without impacting blood glucose or lean muscle mass. Functioning as a fat-burning analog of HGH, AOD 9604 supports lipolysis and helps inhibit lipogenesis, the formation of new fat cells. Unlike traditional HGH therapies, this compound zeroes in on fat loss alone, avoiding broader anabolic effects. Clinical literature has highlighted its ability to reduce resistant fat deposits, particularly in the midsection, while preserving lean muscle.
References
- Ng FM, et al. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res. 2000;53(6):274-278. PMID: 11146367 | DOI: 10.1159/000053183
- Heffernan MA, et al. Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. Int J Obes Relat Metab Disord. 2001;25(10):1442-1449. PMID: 11673763 | DOI: 10.1038/sj.ijo.0801740
- Cox HD, et al. Detection and in vitro metabolism of AOD9604. Drug Test Anal. 2015;7(1):31-38. PMID: 25208511 | DOI: 10.1002/dta.1715
